Haloperidol Neuraxpharm

Haloperidol Neuraxpharm is a prescription medication that contains the active ingredient haloperidol, a butyrophenone antipsychotic, provided in oral dosage form. Marketed in the European Union, this generic product does not list a specific strength, reflecting the standard formulation of haloperidol. It is intended for use under medical supervision for conditions that require dopamine D2 receptor antagonism. The drug is supplied as tablets and is classified as prescription‑only.

Haloperidol Neuraxpharm is indicated for several psychiatric and neurological conditions where dopamine blockade is therapeutic.

- Long‑term management of schizophrenia, including control of acute exacerbations and maintenance of symptom stability. - Treatment of acute psychotic episodes that are not attributable to schizophrenia, such as drug‑induced or brief psychotic disorder. - Control of severe agitation or aggression in inpatient or emergency settings, often as a short‑term intervention. - Adjunct therapy for manic episodes in bipolar disorder when rapid stabilization is required. - Reduction of motor and vocal tics in Tourette syndrome, particularly in patients unresponsive to first‑line agents. - Short‑term relief of severe anxiety or distress associated with psychotic states, used under close supervision.

Haloperidol Neuraxpharm, like other haloperidol products, may cause a range of adverse effects that vary in frequency and severity. When prescribing, clinicians should monitor patients for both common and serious reactions.

Common: - Drowsiness, sedation, or fatigue. - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Dry mouth and constipation. - Blurred vision or dizziness. - Weight gain or changes in appetite. - Hormonal changes such as elevated prolactin levels, which may cause menstrual irregularities or galactorrhea.

Serious: - Neuroleptic malignant syndrome, a life‑threatening reaction with fever, muscle rigidity, and autonomic instability. - Torsades de pointes or other serious cardiac arrhythmias, especially in patients with pre‑existing QT prolongation. - Severe depression or suicidal thoughts, which require immediate evaluation.

The frequency of each effect depends on dose, duration of therapy, and individual patient factors.

When prescribing Haloperidol Neuraxpharm, clinicians should consider several precautions to minimize risk and ensure safe use.

- Assess for a history of cardiovascular disease, especially prolonged QT interval, before initiating therapy. - Use the lowest effective dose and limit duration to reduce the risk of extrapyramidal symptoms. - Monitor for signs of neuroleptic malignant syndrome, particularly during dose escalation. - Evaluate prolactin levels in patients who develop menstrual disturbances or galactorrhea. - Caution in elderly patients with dementia-related psychosis due to increased mortality risk. - Avoid abrupt discontinuation; taper gradually to prevent withdrawal or rebound psychosis.

Haloperidol Neuraxpharm can interact with other medications, affecting its efficacy or safety profile.

Avoid: - Concomitant use with other potent dopamine antagonists, which may intensify extrapyramidal effects. - Co‑administration with drugs that markedly prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics. - Avoid simultaneous use with strong CYP2D6 inhibitors, which can significantly increase haloperidol concentrations.

Use with caution: - Combining with CNS depressants (e.g., benzodiazepines, opioids) may increase sedation and respiratory depression. - Use together with anticholinergic agents may mask early signs of extrapyramidal symptoms. - Interaction with CYP3A4 inhibitors (e.g., ketoconazole) can raise haloperidol plasma levels. - Caution when combined with antihypertensive agents, as haloperidol may cause orthostatic hypotension.